SphynKx: Solving the S1P riddle
SphynKx developing modulators of endogenous S1P to treat fibrosis
The company's lead program focuses on preventing fibrosis in chronic kidney disease by increasing circulating sphingosine 1-phosphate (S1P). A less advanced program seeks to treat idiopathic pulmonary fibrosis (IPF) by lowering S1P.
S1P is a bioactive lipid involved in a host of cellular processes including cell growth, differentiation and survival. It also regulates processes that promote